 Tonix Pharmaceuticals Holding Corp NASDAQ: TNXP has enrolled the first patient in the new Phase 3 RESILIENT study of TNX-102 SL cyclobenzaprine HCl sublingual tablets 5.6 mg for the management of fibromyalgia. An interim analysis by an Independent Data Monitoring Committee of. 